DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10

Disclosed are compounds of formula (I) or any tautomer, stereoisomer, enantiomer, diastereomer, polymorph, pharmaceutically acceptable salt, pharmaceutically acceptable hydrate, pharmaceutically acceptable solvate, or N-oxide thereof, and methods for their preparation. Specific examples of a compound of formula (I) include: 1-(4-Methoxydibenzo[b,d]furan-1-yl)-4-oxocyclohexanecarbonitrile, Ethyl 6-cyano-6-(4-methoxydibenzo[b,d]furan-1-yl)-2-methyl-5,6,7,8-tetrahydroquinoline-3-carboxylate, and Ethyl { [6-cyano-6-(4-methoxydibenzo[b,d]furan-1-yl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]oxy} acetate. Also disclosed are the use of compounds of formula (I) in treating allergic inflammatory conditions such as bronchial asthma, nephritis and allergic rhinitis, and more broadly, for treating asthma, chronic obstructive pulmonary disorder (COPD), allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and a central nervous system (CNS) disorder.